In Vitro Assay of Plasmodium-Infected Red Blood Cell Killing by Cytotoxic Lymphocytes
August 17th, 2022
Here we describe a new method to help elucidate the mechanisms of cellular immunity to Plasmodium during the blood stage of infection. This is an in vitro assay that measures infected red blood cell killing by cytotoxic lymphocytes.
Overview
This article describes a novel in vitro assay designed to investigate cellular immunity mechanisms against Plasmodium during the blood stage of malaria infection. The assay focuses on measuring the killing of infected red blood cells by cytotoxic lymphocytes, providing insights into protective immunity.
Key Study Components
Area of Science
- Cellular Immunity
- Malaria Pathogenesis
- In Vitro Assays
Background
- Understanding protective immunity to malaria is crucial for developing new therapies.
- The mechanisms of cellular immunity during the blood stage of Plasmodium infection are not fully elucidated.
- This study aims to provide a better understanding of these mechanisms.
- The assay can be applied to both human and animal samples.
Purpose of Study
- To explore the mechanisms of cellular immunity to malaria.
- To identify new therapeutic targets for malaria treatment.
- To accelerate the development of malaria vaccines.
Methods Used
- Aspirating heparin solution into a syringe for sample preparation.
- Measuring the efficacy of cytotoxic lymphocytes in killing infected red blood cells.
- Utilizing both human and animal samples in the assay.
- Demonstrating the procedure by researchers in the lab.
Main Results
- The assay successfully measures the killing of infected red blood cells.
- Insights gained could lead to new therapeutic targets.
- The methodology enhances understanding of malaria pathogenesis.
- Potential applications in vaccine development are highlighted.
Conclusions
- This in vitro assay represents a significant advancement in malaria research.
- Understanding cellular immunity mechanisms is essential for future therapies.
- The study opens avenues for further research into malaria immunity.
Frequently Asked Questions
Executive Industry Relevance
Cell-mediated immunity to malaria remains a critical knowledge gap, limiting predictive confidence in vaccine and therapeutic development. This in vitro assay enables direct quantification of cytotoxic lymphocyte-mediated killing of Plasmodium-infected red blood cells, supporting mechanistic de-risking at the discovery stage. The platform advances portfolio decision-making by clarifying immune effector function and enabling translational continuity from discovery to preclinical research.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of cytotoxic lymphocyte function against Plasmodium-infected targets.
- Supports mechanistic de-risking by quantifying effector-mediated iRBC lysis.
- Facilitates functional target validation for immune-based malaria interventions.
- Provides data to inform predictive confidence in immune pathway targeting.
Screening & Assay Development
- Establishes a reproducible, flow cytometry-based assay for iRBC lysis quantification.
- Standardizes effector:target ratio testing for comparative immune cell evaluation.
- Enables scalable screening of cytotoxic cell populations and candidate interventions.
- Delivers quantitative outputs suitable for downstream compound or biologic assessment.
Translational & Preclinical Research
- Aligns in vitro immune function with disease-relevant blood-stage malaria models.
- Supports continuity from cellular mechanism discovery to preclinical validation of immune interventions.
- Enables risk-adjusted advancement of vaccine and immunotherapy candidates.
- Provides a platform for mechanistic studies using blocking antibodies or receptor-specific interventions.
Pipeline & Workflow Integration
This assay bridges early discovery and preclinical research by enabling direct measurement of immune effector function against Plasmodium-infected cells.
- Discovery Biology: Supports hypothesis testing on cytotoxic lymphocyte roles in malaria immunity.
- Screening: Provides standardized, quantitative lysis readouts for immune cell and intervention evaluation.
- Analytics: Delivers flow cytometry-based measurements and statistical analysis of lysis percentages.
- Translational Research: Connects in vitro immune function to preclinical malaria models for candidate prioritization.
- Enterprise Reuse: Adaptable to both human and animal samples, supporting broad R&D portfolio needs.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in immune target validation and mechanistic understanding.
- Operational Value: Standardizes immune cell function assays for reproducibility and scalability.
- Strategic Value: Informs go/no-go decisions for immune-based malaria interventions and vaccine candidates.
- Portfolio Impact: Enables risk-adjusted prioritization of immunotherapeutic and vaccine programs.
Implementation Considerations
- Requires expertise in flow cytometry and immune cell isolation.
- Needs access to animal or human blood samples and cell sorting infrastructure.
- Demands cross-team standardization of effector:target ratios and gating strategies.
- Adaptable to different Plasmodium species and cytotoxic cell types.
- Dependent on robust controls for spontaneous lysis and statistical analysis.
Biopharma FAQs
Chapters in this video
0:04
Introduction
0:58
Experimental Malaria Infection in Mouse
1:49
Obtaining Fresh Whole Mouse Splenocytes
3:30
Cytotoxic Effector Cell Purification: CD8a+ T Cell Negative Selection
4:22
P. yoelii Infected RBC Isolation
5:21
CFSE Labeling of RBCs, Preparation for Flow Cytometry and Cytotoxic Lymphocyte Coculture
6:22
Results: P. yoelii - iRBC Enrichment and Assessment of cell lysis Percentage of P. yoelii - iRBCs by CD8+ lymphocytes
7:39
Conclusion
